NASDAQ · GLTO
Healthcare · Biotechnology
$28.69
Down-$0.75 (-3.36%)
Updated Aug 16, 2026, 3:37 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
GLTO does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning GLTO.
GLTO research
Company profile and research snapshot.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 17, 2026 | UBS | Buy | — |
| Feb 17, 2026 | Guggenheim | Buy | — |
| Jan 7, 2026 | Leerink Partners | Outperform | — |
| Dec 8, 2025 | Guggenheim | Buy | — |
| Dec 1, 2025 | Guggenheim | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 9, 2026
Galecto, Inc. (Galecto or the Company) (NASDAQ: GLTO), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced its name change to Damora Therapeutics, Inc.
Benzinga · Feb 17, 2026
UBS analyst Michael Yee initiates coverage on Galecto (NASDAQ:GLTO) with a Buy rating and announces Price Target of $45.
Benzinga · Feb 17, 2026
Guggenheim analyst Brad Canino maintains Galecto (NASDAQ:GLTO) with a Buy and raises the price target from $36 to $40.
Yahoo · Feb 12, 2026
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the closing of its previously announced underwritten public offering of 16,644,737 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 2,171,052 additional shares, at a public offering price of $19.00 per share. The aggr
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GLTO.
